CD36 CVD Cardiometabolic disease ER stress HFD Liver disease NAFLD

Journal

JHEP reports : innovation in hepatology
ISSN: 2589-5559
Titre abrégé: JHEP Rep
Pays: Netherlands
ID NLM: 101761237

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 13 04 2019
revised: 16 10 2019
accepted: 24 10 2019
entrez: 11 2 2020
pubmed: 11 2 2020
medline: 11 2 2020
Statut: epublish

Résumé

The fatty acid translocase, also known as CD36, is a well-established scavenger receptor for fatty acid (FA) uptake and is abundantly expressed in many metabolically active tissues. In the liver, CD36 is known to contribute to the progression of non-alcoholic fatty liver disease and to the more severe non-alcoholic steatohepatitis, by promoting triglyceride accumulation and subsequent lipid-induced endoplasmic reticulum (ER) stress. Given the recent discovery that the hepatocyte-secreted proprotein convertase subtilisin/kexin type 9 (PCSK9) blocks CD36 expression, we sought to investigate the role of PCSK9 in liver fat accumulation and injury in response to saturated FAs and in a mouse model of diet-induced hepatic steatosis. In this study, we investigated the role of PCSK9 on the uptake and accumulation of FAs, as well as FA-induced toxicity, in a variety of cultured hepatocytes. Diet-induced hepatic steatosis and liver injury were also assessed in Our results indicate that PCSK9 deficiency in cultured hepatocytes increased the uptake and accumulation of saturated and unsaturated FAs. In the presence of saturated FAs, PCSK9 also protected cultured hepatocytes from ER stress and cytotoxicity. In line with these findings, a metabolic challenge using a high-fat diet caused severe hepatic steatosis, ER stress inflammation and fibrosis in the livers of Collectively, our findings demonstrate that PCSK9 regulates hepatic triglyceride content in a manner dependent on CD36. In the presence of excess dietary fats, PCSK9 can also protect against hepatic steatosis and liver injury. The proprotein convertase subtilisin/kexin type 9 (PCSK9) is a circulating protein known to reduce the abundance of receptors on the surface of liver cells charged with the task of lipid uptake from the circulation. Although PCSK9 deficiency is known to cause lipid accumulation in mice and in cultured cells, the toxicological implications of this observation have not yet been reported. In this study, we demonstrate that PCSK9 can protect against cytotoxicity in cultured liver cells treated with a saturated fatty acid and we also show that

Identifiants

pubmed: 32039393
doi: 10.1016/j.jhepr.2019.10.009
pii: S2589-5559(19)30131-4
pmc: PMC7005770
doi:

Types de publication

Journal Article

Langues

eng

Pagination

418-429

Informations de copyright

© 2019 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).

Références

Mol Syst Biol. 2017 Aug 21;13(8):938
pubmed: 28827398
Arterioscler Thromb Vasc Biol. 2014 Jan;34(1):26-33
pubmed: 24202306
Circulation. 2015 Jan 27;131(4):e29-322
pubmed: 25520374
Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):928-33
pubmed: 12552133
Eur Heart J. 2019 Jan 21;40(4):357-368
pubmed: 29982592
J Biol Chem. 2008 Jan 25;283(4):2363-72
pubmed: 18039658
PLoS One. 2013 May 13;8(5):e64145
pubmed: 23675525
Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16314-9
pubmed: 18852460
Ann Intern Med. 2018 Mar 6;168(5):376-379
pubmed: 29181527
Lancet Diabetes Endocrinol. 2017 Feb;5(2):97-105
pubmed: 27908689
Gastroenterology. 2008 Feb;134(2):568-76
pubmed: 18082745
World J Gastroenterol. 2014 Feb 21;20(7):1768-76
pubmed: 24587654
J Biol Chem. 2019 Jun 7;294(23):9037-9047
pubmed: 31004037
JCI Insight. 2017 May 18;2(10):
pubmed: 28515357
J Clin Endocrinol Metab. 2009 Jul;94(7):2537-43
pubmed: 19351729
Ann Med. 2016 Aug;48(5):384-91
pubmed: 27222915
J Biol Chem. 2013 May 31;288(22):15547-55
pubmed: 23603908
J Lipid Res. 2008 May;49(5):1068-76
pubmed: 18227531
J Vis Exp. 2013 May 07;(75):e50317
pubmed: 23685703
Proc Natl Acad Sci U S A. 2004 May 4;101(18):7100-5
pubmed: 15118091
J Biol Chem. 2018 May 11;293(19):7329-7343
pubmed: 29593095
Cell Death Dis. 2015 Nov 19;6:e1976
pubmed: 26583319
FEBS Lett. 2010 Feb 19;584(4):701-6
pubmed: 20026049
J Mol Cell Cardiol. 2015 May;82:186-93
pubmed: 25791168
Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1484-93
pubmed: 23559630
Diabetes Metab. 2008 Dec;34(6 Pt 2):649-57
pubmed: 19195626
World J Gastrointest Pathophysiol. 2017 May 15;8(2):51-58
pubmed: 28573067
Am J Physiol Endocrinol Metab. 2001 Aug;281(2):E275-82
pubmed: 11440903
J Mol Cell Cardiol. 2010 Jun;48(6):1105-10
pubmed: 19913545
N Engl J Med. 2017 May 4;376(18):1713-1722
pubmed: 28304224
Atherosclerosis. 2018 Nov;278:82-90
pubmed: 30261472
J Endocrinol. 2014 Jan 08;220(2):T1-T23
pubmed: 24281010
EMBO J. 2011 Apr 6;30(7):1357-75
pubmed: 21407177
Endocrinology. 2016 Feb;157(2):570-85
pubmed: 26650570
Arterioscler Thromb Vasc Biol. 2011 Apr;31(4):785-91
pubmed: 21273557
J Hepatol. 2016 Aug;65(2):425-43
pubmed: 27091791
EMBO J. 2004 Feb 25;23(4):950-8
pubmed: 14765107
Exp Mol Med. 2014 Jun 06;46:e99
pubmed: 24903227
Arterioscler Thromb Vasc Biol. 2015 Dec;35(12):2517-25
pubmed: 26494228
Aliment Pharmacol Ther. 2011 Aug;34(3):274-85
pubmed: 21623852
Am J Physiol Endocrinol Metab. 2006 Aug;291(2):E275-81
pubmed: 16492686

Auteurs

Paul F Lebeau (PF)

Department of Medicine, Division of Nephrology, McMaster University, St. Joseph's Healthcare Hamilton, Ontario L8N 4A6, Canada.

Jae Hyun Byun (JH)

Department of Medicine, Division of Nephrology, McMaster University, St. Joseph's Healthcare Hamilton, Ontario L8N 4A6, Canada.

Khrystyna Platko (K)

Department of Medicine, Division of Nephrology, McMaster University, St. Joseph's Healthcare Hamilton, Ontario L8N 4A6, Canada.

Ali A Al-Hashimi (AA)

Department of Medicine, Division of Nephrology, McMaster University, St. Joseph's Healthcare Hamilton, Ontario L8N 4A6, Canada.

Šárka Lhoták (Š)

Department of Medicine, Division of Nephrology, McMaster University, St. Joseph's Healthcare Hamilton, Ontario L8N 4A6, Canada.

Melissa E MacDonald (ME)

Department of Medicine, Division of Nephrology, McMaster University, St. Joseph's Healthcare Hamilton, Ontario L8N 4A6, Canada.

Aurora Mejia-Benitez (A)

Department of Medicine, Division of Nephrology, McMaster University, St. Joseph's Healthcare Hamilton, Ontario L8N 4A6, Canada.

Annik Prat (A)

Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, affiliated to the University of Montreal, Montreal, Quebec H2W 1R7, Canada.

Suleiman A Igdoura (SA)

Department of Biology and Pathology, McMaster University, Hamilton, Ontario, L8S 4K1, Canada.

Bernardo Trigatti (B)

Thrombosis and Atherosclerosis Research Institute (TaARI), Hamilton Health Sciences and McMaster University, Hamilton, Ontario L8L 2X2, Canada.
Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario L8S 4L8, Canada.

Kenneth N Maclean (KN)

the Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA, 80045.

Nabil G Seidah (NG)

Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, affiliated to the University of Montreal, Montreal, Quebec H2W 1R7, Canada.

Richard C Austin (RC)

Department of Medicine, Division of Nephrology, McMaster University, St. Joseph's Healthcare Hamilton, Ontario L8N 4A6, Canada.

Classifications MeSH